RIGL · Insider Trading
Rigel Pharmaceuticals Inc. (New)
Every open-market purchase and sale reported by RIGL officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-09-03 | David A Santos | EVP, Chief Commercial Officer | F | −874 | −$41.52K |
| 2026-09-03 | Raymond J. Furey | EVP, GC, CCO & Corp Sec | F | −877 | −$41.66K |
| 2026-09-03 | Raul R Rodriguez | CEO, President | F | −2,424 | −$115.14K |
| 2026-09-03 | Dean L Schorno | EVP & Chief Financial Officer | MIXED | +3,672 | +$55.85K |
| 2026-07-10 | Alison L. Hannah | EVP, Chief Medical Officer | A | +24,400 | — |
| 2026-06-24 | Kamil Ali-Jackson | Director | Sell | −2,500 | −$87.50K |
| 2026-06-22 | David A Santos | EVP, Chief Commercial Officer | A | +7,394 deriv. | — |
| 2026-06-22 | Raymond J. Furey | EVP, GC, CCO & Corp Sec | A | +7,394 deriv. | — |
| 2026-06-22 | Raul R Rodriguez | CEO, President | A | +31,700 deriv. | — |
| 2026-06-22 | Dean L Schorno | EVP & Chief Financial Officer | A | +7,394 deriv. | — |
| 2026-06-22 | Lisa Rojkjaer | EVP, Chief Medical Officer | A | +16,769 deriv. | — |
| 2026-06-03 | Dean L Schorno | EVP & Chief Financial Officer | MIXED | +2,453 | +$22.43K |
| 2026-06-03 | David A Santos | EVP, Chief Commercial Officer | F | −874 | −$26.10K |
| 2026-06-03 | Raymond J. Furey | EVP, GC, CCO & Corp Sec | F | −877 | −$26.19K |
| 2026-06-03 | Raul R Rodriguez | CEO, President | F | −2,424 | −$72.38K |
| 2026-06-03 | Lisa Rojkjaer | EVP, Chief Medical Officer | F | −850 | −$25.38K |
| 2026-05-28 | Kamil Ali-Jackson | Director | Sell | −2,500 | −$72.92K |
| 2026-05-19 | Jane Wasman | Director | A | +5,750 | — |
| 2026-05-19 | Mark W Frohlich | Director | A | +5,750 | — |
| 2026-05-19 | Alison L. Hannah | Director | A | +5,750 | — |
| 2026-05-19 | Anthony Gregg Lapointe | Director | A | +5,750 | — |
| 2026-05-19 | Walter H Moos | Director | A | +5,750 | — |
| 2026-05-19 | Michael Patrick Miller | Director | A | +5,750 | — |
| 2026-05-19 | Kamil Ali-Jackson | Director | A | +5,750 | — |
| 2026-02-24 | Walter H Moos | Director | MIXED | — | −$49.44K |
| 2026-02-19 | Dean L Schorno | EVP & Chief Financial Officer | A | +20,636 | — |
| 2026-02-19 | Raul R Rodriguez | CEO, President | A | +53,915 | — |
| 2026-02-19 | Raymond J. Furey | EVP, GC, CCO & Corp Sec | A | +19,497 | — |
| 2026-02-19 | Lisa Rojkjaer | EVP, Chief Medical Officer | A | +18,894 | — |
| 2026-02-19 | David A Santos | EVP, Chief Commercial Officer | A | +19,430 | — |
| 2026-02-12 | Dean L Schorno | EVP & Chief Financial Officer | F | −3,546 | −$122.76K |
| 2026-02-12 | Raymond J. Furey | EVP, GC, CCO & Corp Sec | F | −3,546 | −$122.76K |
| 2026-02-12 | Lisa Rojkjaer | EVP, Chief Medical Officer | F | −3,758 | −$130.10K |
| 2026-02-12 | Raul R Rodriguez | CEO, President | F | −7,607 | −$263.35K |
| 2026-02-12 | David A Santos | EVP, Chief Commercial Officer | F | −3,546 | −$122.76K |
| 2026-02-04 | Raymond J. Furey | EVP, GC, CCO & Corp Sec | F | −3,968 | −$142.89K |
| 2026-02-04 | Dean L Schorno | EVP & Chief Financial Officer | F | −5,488 | −$197.62K |
| 2026-02-04 | David A Santos | EVP, Chief Commercial Officer | F | −5,718 | −$205.91K |
| 2026-02-04 | Raul R Rodriguez | CEO, President | MIXED | −4,745 | −$929.60K |
| 2026-02-03 | Michael Patrick Miller | Director | A | +12,000 deriv. | — |
| 2025-12-29 | Dean L Schorno | EVP & Chief Financial Officer | M | +6,500 | +$139.79K |
| 2025-09-17 | Raul R Rodriguez | CEO, President | A | +31,700 deriv. | — |
| 2025-09-17 | Dean L Schorno | EVP & Chief Financial Officer | A | +7,394 deriv. | — |
| 2025-09-17 | Lisa Rojkjaer | EVP, Chief Medical Officer | A | +7,394 deriv. | — |
| 2025-09-17 | David A Santos | EVP, Chief Commercial Officer | A | +7,394 deriv. | — |
| 2025-09-17 | Raymond J. Furey | EVP, GC, CCO & Corp Sec | A | +7,394 deriv. | — |
| 2025-05-28 | Jane Wasman | Director | A | +2,500 | — |
| 2025-05-28 | Kamil Ali-Jackson | Director | A | +2,500 | — |
| 2025-05-28 | Mark W Frohlich | Director | A | +1,250 | — |
| 2025-05-28 | Alison L. Hannah | Director | A | +2,500 | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Raul R Rodriguez | CEO, President | 273,362 | $13.64M |
| Dean L Schorno | EVP & Chief Financial Officer | 78,362 | $3.91M |
| David A Santos | EVP, Chief Commercial Officer | 61,622 | $3.08M |
| Raymond J. Furey | EVP, GC, CCO & Corp Sec | 50,559 | $2.52M |
| Alison L. Hannah | EVP, Chief Medical Officer | 35,025 | $1.75M |
| Lisa Rojkjaer | EVP, Chief Medical Officer | 34,003 | $1.70M |
| Walter H Moos | Director | 18,472 | $921.94K |
| Anthony Gregg Lapointe | Director | 18,250 | $910.86K |
| Jane Wasman | Director | 18,250 | $910.86K |
| Kamil Ali-Jackson | Director | 10,125 | $505.34K |
| Mark W Frohlich | Director | 7,000 | $349.37K |
| Michael Patrick Miller | Director | 5,937 | $296.32K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the RIGL quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.